Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as SCH 900636
Org 34517 · 2 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| Org 34517 | EXPERIMENTAL | Org 34517 titrated to 900 mg daily for 2 weeks |
| Placebo | PLACEBO_COMPARATOR | - |
| Org 34517_1 | EXPERIMENTAL | low dose Org 34517 |
| Org 34517_2 | EXPERIMENTAL | high dose Org 34517 |
| Name | Type | Description |
|---|---|---|
| SCH 900636 | DRUG | Org 34517 300 mg on Day 1, 600 mg on Day 2, then 900 mg daily starting from Day 3. Subjects in this arm were also to continue the "usual treatment" for psychotic major depression. |
| Placebo | DRUG | Placebo |
| Org 34517 | DRUG | low dose Org 34517 |
Inclusion Criteria: * have attended Screening, Baseline, Visit Day 15, Day 29 and Day 43 of previous trial 28130; * have a CGI of Severity score of 3 or greater at Day 43 of previous trial 28130 and at Day 1 of current trial 28133, or a lower score when the investigator is of the opinion that furth...
Org 34517 is an investigational small molecule being studied for the treatment of depression, specifically as an adjunctive therapy in subjects with psychotic major depression. It is being developed by Merck & Company, Inc. (MRK) and is currently in Phase 2 clinical development.
Org 34517 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The drug is currently in Phase 2 clinical development for the treatment of depression.
Org 34517 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 clinical trial has been completed to evaluate its efficacy and safety as adjunctive therapy in subjects with psychotic major depression.
Org 34517 has been studied in one completed Phase 2 clinical trial, identified as NCT00212797. This randomized, double-blind, placebo-controlled study enrolled 273 participants and evaluated the efficacy and safety of two doses of Org 34517 as adjunctive therapy in subjects with psychotic major depression.
Org 34517 is the primary name used for this investigational drug in clinical development. No alternative names have been established for this compound in the available clinical trial information.